These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17442286)

  • 1. Analysis of vaccine's schedules using models.
    Pappalardo F; Motta S; Lollini PL; Mastriani E
    Cell Immunol; 2006 Dec; 244(2):137-40. PubMed ID: 17442286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and simulation of cancer immunoprevention vaccine.
    Pappalardo F; Lollini PL; Castiglione F; Motta S
    Bioinformatics; 2005 Jun; 21(12):2891-7. PubMed ID: 15817697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Searching of optimal vaccination schedules: application of genetic algorithms to approach the problem in cancer immunoprevention.
    Pennisi MA; Pappalardo F; Zhang P; Motta S
    IEEE Eng Med Biol Mag; 2009; 28(4):67-72. PubMed ID: 19622427
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
    Spisek R
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
    J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
    Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
    Dharmapuri S; Aurisicchio L; Neuner P; Verdirame M; Ciliberto G; La Monica N
    Cancer Gene Ther; 2009 May; 16(5):462-72. PubMed ID: 18989354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
    Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
    Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator.
    Lollini PL; Motta S; Pappalardo F
    BMC Bioinformatics; 2006 Jul; 7():352. PubMed ID: 16857043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
    Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
    J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
    Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
    Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer.
    Bird RC; Deinnocentes P; Lenz S; Thacker EE; Curiel DT; Smith BF
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):289-304. PubMed ID: 18423623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
    De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL
    Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
    Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
    Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel murine model of allogeneic vaccination against renal cancer.
    Havranek EG; Labarthe MC; Ward S; Anderson CJ; Whelan MA; Pandha H
    BJU Int; 2008 May; 101(9):1165-9. PubMed ID: 18399831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.